Filing Details
- Accession Number:
- 0001209191-23-006371
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-02 18:13:45
- Reporting Period:
- 2023-01-31
- Accepted Time:
- 2023-02-02 18:13:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1435049 | Chinook Therapeutics Inc. | KDNY | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1823187 | James Andrew King | C/O Chinook Therapeutics, Inc. 400 Fairview Ave. No., 9Th Floor Seattle WA 98109 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-31 | 8,333 | $0.00 | 18,325 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-31 | 3,244 | $24.68 | 15,081 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unirt | Disposition | 2023-01-31 | 8,333 | $0.00 | 8,333 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-01-31 | 104,000 | $0.00 | 104,000 | $25.27 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2023-01-31 | 26,000 | $0.00 | 26,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 16,667 | No | 4 | M | Direct | ||
| 104,000 | 2033-01-30 | No | 4 | A | Direct | |
| 26,000 | No | 4 | A | Direct |
Footnotes
- Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
- The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
- The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
Billionaire Hedge Funds
